Lipids: Effectors in Innate Immunity

脂质:先天免疫的效应器

基本信息

  • 批准号:
    6825790
  • 负责人:
  • 金额:
    $ 19.33万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2004
  • 资助国家:
    美国
  • 起止时间:
    2004-07-01 至 2006-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Innate immunity has evolved as the first line defense against microbial proliferation and invasion on body surfaces through effectors that are preformed or available within hours. Much attention has been given to the epithelial cells lining mucosal body surfaces and to the overlaying fluid, which is rich in mucins and antimicrobial (poly) peptides, for example lysozyme. However, though all body fluids also contain lipids, including free fatty acids and phospholipids, only in the lung, surfactant factor associated with proteins has been welt documented as defense molecule. Supported by numerous reports of antimicrobial activity of fatty acids, alterations of fatty acid profiles in certain infectious diseases, documentation of an intestinal surfactant-like particle and our preliminary data indicating a synergism between lysozyme and selected fatty acids, we propose that lipids including free fatty acids secreted by epithelial cells are an indispensable arm of host defense acting independently or in synergy with other defense molecules. To test this hypothesis we will take 3 approaches with the following specific aims. We will determine whether: (1) Inhibition of epithelial lipid secretion leads to enhanced microbial proliferation, and (2) selective removal of lipids from nasal fluids will decrease the fluid's inherent antimicrobial activity, which can be reversed after resupplementation with the extracted lipids. Mucosal sites investigated will be the sino-nasal region and the genital tract. In vitro models will employ primary epithelial cells and existing immortalized. Cells will be cultured at an air-liquid interface in the presence of radioactively labeled lipids with and without pro-inflammatory stimuli or lipid secretion inhibitors. Lipids from normal nasal fluid will be selectively removed by solid phase extraction with C18-bonded silica and eluted with acetonitrile. Lipids will be identified and quantified using radiographs of developed TLC plates and mass spectrometry techniques. Antimicrobial activity of treated and untreated samples will be assessed by determination of CFUs and microbial metabolic activity using bacteria and yeasts that do not routinely cause infection in the healthy adult and a common STD pathogen. (3) Epithelial lipid effectors identified in aim 1 and 2 bind to the microbial target. Binding of candidate lipid effectors to microbes will be documented and quantified with radioactive binding studies employing liquid scintillation and radiolabeled lipids and with surface plasmon resonance spectrometry. This new concept in innate immunity may have major significance in infectious diseases through providing new aspects in hereditary predisposition to chronic infectious diseases and host pathogen interactions and initiating new approaches to drug development and nutritional recommendations.
描述(由申请人提供):先天免疫已经发展成为通过在数小时内预先形成或可用的效应器对抗微生物增殖和侵入体表的第一线防御。已经给予了很多关注的上皮细胞内衬粘膜体表面和覆盖的流体,这是丰富的粘蛋白和抗微生物(多)肽,例如溶菌酶。然而,尽管所有体液也含有脂质,包括游离脂肪酸和磷脂,但仅在肺中,与蛋白质相关的表面活性因子已被证明是防御分子。支持的脂肪酸的抗微生物活性,在某些感染性疾病中的脂肪酸谱的改变,肠表面活性剂样颗粒的文件和我们的初步数据表明溶菌酶和选定的脂肪酸之间的协同作用的许多报告,我们提出,脂质,包括上皮细胞分泌的游离脂肪酸是一个不可缺少的手臂的主机防御独立或协同作用与其他防御分子。为了验证这一假设,我们将采取3种方法,具体目标如下。我们将确定: (1)上皮脂质分泌的抑制导致微生物增殖增强,以及(2)从鼻液中选择性去除脂质将降低流体的固有抗微生物活性,这可以在用提取的脂质再补充后逆转。研究的粘液组织部位为鼻窦区域和生殖道。体外模型将采用原代上皮细胞和现有的永生化细胞。细胞将在存在放射性标记的脂质的空气-液体界面处培养,存在和不存在促炎刺激物或脂质分泌抑制剂。正常鼻液中的脂质将通过C18键合硅胶固相萃取和乙腈洗脱选择性去除。将使用显色TLC板的射线照片和质谱技术鉴别和定量脂质。通过使用通常不会引起健康成人感染的细菌和酵母菌以及常见STD病原体测定CFU和微生物代谢活性,评估经处理和未经处理样本的抗菌活性。 (3)目的1和2中鉴定的上皮脂质效应物与微生物靶标结合。将记录候选脂质效应物与微生物的结合,并通过采用液体闪烁和放射性标记脂质的放射性结合研究以及表面等离子体共振光谱法进行定量。先天免疫的这一新概念可能通过提供慢性传染病遗传易感性和宿主病原体相互作用的新方面,并启动药物开发和营养建议的新方法,对传染病具有重大意义。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

EDITH PORTER其他文献

EDITH PORTER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('EDITH PORTER', 18)}}的其他基金

Lipid Effector Molecules of Innate Immunity: Antimicrobial Cholesteryl Esters
先天免疫的脂质效应分子:抗菌胆固醇酯
  • 批准号:
    8475619
  • 财政年份:
    2011
  • 资助金额:
    $ 19.33万
  • 项目类别:
Lipid Effector Molecules of Innate Immunity: Antimicrobial Cholesteryl Esters
先天免疫的脂质效应分子:抗菌胆固醇酯
  • 批准号:
    8274652
  • 财政年份:
    2011
  • 资助金额:
    $ 19.33万
  • 项目类别:
Lipid Effector Molecules of Innate Immunity: Antimicrobial Cholesteryl Esters
先天免疫的脂质效应分子:抗菌胆固醇酯
  • 批准号:
    8668077
  • 财政年份:
    2011
  • 资助金额:
    $ 19.33万
  • 项目类别:
Lipid Effector Molecules of Innate Immunity: Antimicrobial Cholesteryl Esters
先天免疫的脂质效应分子:抗菌胆固醇酯
  • 批准号:
    8078425
  • 财政年份:
    2011
  • 资助金额:
    $ 19.33万
  • 项目类别:
NOVEL DRUG DESIGN AND HIGH THROUGHPUT SCREENING
新颖的药物设计和高通量筛选
  • 批准号:
    7161228
  • 财政年份:
    2005
  • 资助金额:
    $ 19.33万
  • 项目类别:
Lipids: Effectors in Innate Immunity
脂质:先天免疫的效应器
  • 批准号:
    6913701
  • 财政年份:
    2004
  • 资助金额:
    $ 19.33万
  • 项目类别:
NOVEL DRUG DESIGN AND HIGH THROUGHPUT SCREENING
新颖的药物设计和高通量筛选
  • 批准号:
    7547671
  • 财政年份:
  • 资助金额:
    $ 19.33万
  • 项目类别:
NOVEL DRUG DESIGN AND HIGH THROUGHPUT SCREENING
新颖的药物设计和高通量筛选
  • 批准号:
    7682570
  • 财政年份:
  • 资助金额:
    $ 19.33万
  • 项目类别:
NOVEL DRUG DESIGN AND HIGH THROUGHPUT SCREENING
新颖的药物设计和高通量筛选
  • 批准号:
    7547674
  • 财政年份:
  • 资助金额:
    $ 19.33万
  • 项目类别:
NOVEL DRUG DESIGN AND HIGH THROUGHPUT SCREENING
新颖的药物设计和高通量筛选
  • 批准号:
    7902212
  • 财政年份:
  • 资助金额:
    $ 19.33万
  • 项目类别:

相似海外基金

FAIRClinical: FAIR-ification of Supplementary Data to Support Clinical Research
FAIRClinical:补充数据的 FAIR 化以支持临床研究
  • 批准号:
    EP/Y036395/1
  • 财政年份:
    2024
  • 资助金额:
    $ 19.33万
  • 项目类别:
    Research Grant
Optimizing integration of veterinary clinical research findings with human health systems to improve strategies for early detection and intervention
优化兽医临床研究结果与人类健康系统的整合,以改进早期检测和干预策略
  • 批准号:
    10764456
  • 财政年份:
    2023
  • 资助金额:
    $ 19.33万
  • 项目类别:
The IDeA State Consortium for a Clinical Research Resource Center: Increasing Clinical Trials in IDeA States through Communication of Opportunities, Effective Marketing, and WorkforceDevelopment
IDeA 州临床研究资源中心联盟:通过机会交流、有效营销和劳动力发展增加 IDeA 州的临床试验
  • 批准号:
    10715568
  • 财政年份:
    2023
  • 资助金额:
    $ 19.33万
  • 项目类别:
The Mayo Clinic NeuroNEXT Clinical Research Site
梅奥诊所 NeuroNEXT 临床研究网站
  • 批准号:
    10743328
  • 财政年份:
    2023
  • 资助金额:
    $ 19.33万
  • 项目类别:
Addressing Underperformance in Clinical Trial Enrollments: Development of a Clinical Trial Toolkit and Expansion of the Clinical Research Footprint
解决临床试验注册表现不佳的问题:开发临床试验工具包并扩大临床研究足迹
  • 批准号:
    10638813
  • 财政年份:
    2023
  • 资助金额:
    $ 19.33万
  • 项目类别:
Improving Multicultural Engagement in Clinical Research through Partnership with Federally Qualified Health Centers and Community Health Worker Programs
通过与联邦合格的健康中心和社区卫生工作者计划合作,改善临床研究中的多元文化参与
  • 批准号:
    10823828
  • 财政年份:
    2023
  • 资助金额:
    $ 19.33万
  • 项目类别:
The Minnesota TMD IMPACT Collaborative: Integrating Basic/Clinical Research Efforts and Training to Improve Clinical Care
明尼苏达州 TMD IMPACT 协作:整合基础/临床研究工作和培训以改善临床护理
  • 批准号:
    10828665
  • 财政年份:
    2023
  • 资助金额:
    $ 19.33万
  • 项目类别:
Promoting a Culture Of Innovation, Mentorship, Diversity and Opportunity in NCI Sponsored Clinical Research: NCI Research Specialist (Clinician Scientist) Award Application of Janice M. Mehnert, M.D.
在 NCI 资助的临床研究中促进创新、指导、多样性和机会文化:Janice M. Mehnert 医学博士的 NCI 研究专家(临床科学家)奖申请
  • 批准号:
    10721095
  • 财政年份:
    2023
  • 资助金额:
    $ 19.33万
  • 项目类别:
Clinical Research Center for REstoration of NEural-based Function in the Real World (RENEW)
现实世界神经功能恢复临床研究中心 (RENEW)
  • 批准号:
    10795328
  • 财政年份:
    2023
  • 资助金额:
    $ 19.33万
  • 项目类别:
Mentoring Scientists for Careers in HIV Translational Clinical Research
指导科学家从事艾滋病毒转化临床研究
  • 批准号:
    10762827
  • 财政年份:
    2023
  • 资助金额:
    $ 19.33万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了